default author photo

Barry L. Shulkin

St Jude Children’s Research Hospital - Department of Diagnostic Imaging

262 Danny Thomas Place

Memphis, TN 38105

United States

SCHOLARLY PAPERS

2

DOWNLOADS

151

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Excellent Outcome for Pediatric Patients with High Risk Hodgkin Lymphoma with Brentuximab Vedotin and Risk Adapted Residual Node Radiation

Number of pages: 18 Posted: 29 Oct 2020
St Jude Children’s Research Hospital - Department of Oncology, Stanford University - Division of Pediatric Hematology-Oncology, Nemours/Alfred I. duPont Hospital for Children - Department of Pediatrics, St. Jude Children’s Research Hospital - Department of Oncology, St Jude Children’s Research Hospital - Department of Radiation Oncology, St Jude Children’s Research Hospital - Division of Nursing Research, St. Jude Children’s Research Hospital - Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital - Department of Oncology, Harvard University - Department of Radiation Oncology, Harvard University - Department of Pediatrics, Department of Pediatric Hematology-Oncology, Peoria, University of Colorado, Aurora - Center for Cancer and Blood Disorders, MaineHealth - Maine Children's Cancer Program, St. Jude Children’s Research Hospital - Department of Oncology, St Jude Children’s Research Hospital - Department of Diagnostic Imaging, St Jude Children’s Research Hospital - Department of Biostatistics, St Jude Children’s Research Hospital - Department of Biostatistics, Stanford University - Department of Radiation Oncology, Stanford University - Department of Radiation Oncology, St Jude Children’s Research Hospital - Department of Oncology and St Jude Children’s Research Hospital - Department of Radiation Oncology
Downloads 100 (689,572)

Abstract:

Loading...

Hodgkin lymphoma, Brentuximab vedotin, residual node radiation, response adapted therapy, pediatric, high-risk, frontline trial

2.

Improved Clinical Responses with the Concomitant Use of an Anti-GD2 Monoclonal Antibody During Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma: A New Treatment Paradigm

Number of pages: 31 Posted: 08 Sep 2018
St. Jude Children’s Research Hospital - Department of Oncology, St. Jude Children’s Research Hospital - Department of Oncology, St. Jude Children’s Research Hospital, St Jude Children’s Research Hospital - Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, St Jude Children’s Research Hospital - Department of Radiation Oncology, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital - Department of Oncology, St. Jude Children’s Research Hospital - Department of Oncology, St. Jude Children’s Research Hospital - Department of Oncology, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, St. Jude Children’s Research Hospital, University of Wisconsin-Madison, Provenance Biopharmaceuticals, University of Wisconsin-Madison, Duke-NUS Graduate Medical School Singapore and St. Jude Children’s Research Hospital - Department of Oncology
Downloads 51 (1,052,702)

Abstract:

Loading...

high-risk neuroblastoma, anti-gd2, hu14.18K322A, response